Sánchez Jiménez FJ., et. al. 27. Herrera Malo YE, Leal A, Sinay J, Mejía López A. 177Lu–DOTA– Tyr3–OCTREOTATE para el tratamiento de tumores euroendocrinos gastroenteropancreáticos. Revisión sistemática de la literatura. Reposi-tory. urosario.edu.co. Disponible en: http://repository.urosario.edu.co/ handle/10336/4835?show=full 28. Agencia Europea del Medicamento. Rydapt (MIDOSTAURINA). Dis-ponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medi-cines/ human/medicines/004095/smops/Positive/human_smop_001172. jsp&mid=WC0b01ac058001d127 29. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. 30. Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, et al. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2605-7. 31. Agencia Europea del Medicamento. Kisqali (RIBOCICLIB). Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/me-dicines/ 004213/human_med_002149.jsp&mid=WC0b01ac058001d124 32. Fasching PA, Decker T, Fehm T, Janni W, Kuemmel S, Lueftner D, et al. On-going Clinical Trials Abstract OT2-01-18: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole. Abstracts: 2016 San Antonio Breast Cancer Sym-posium; December 6-10, 2016; San Antonio, Texas. Cancer Res 2017;77(4) Suppl. Unpublished pages. Disponible en: http://cancerres.aacrjournals.org/ content/77/4_Supplement/OT2-01-18 33. Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of ac-tion and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors Clin Cancer Res. 2017 Jul 1;23(13):3251-3262. 34. Tiedt R, Delach S, Kovats S, Horn T, Acker M, Schacher Engstler B, et al. Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib. AACR Annual Meeting 2017; April 1-5; Abstract 2346. Cancer Res 2017;77(13)Suppl. Unpublis-hed pages. Disponible en: http://cancerres.aacrjournals.org/content/77/13_ Supplement/2346 35. Agencia Europea del Medicamento. Vosevi (SOFOSBUVIR/ VELPA-TASVIR/ VOXILAPREVIR). Disponible en: http://www.ema.europa.eu/ 230 Sanid. mil. 2017; 73 (4) docs/en_GB/document_library/EPAR_-_Summary_for_the_public/hu-man/ 004350/WC500235376.pdf 36. Soriano V, Benítez-Gutiérrez L, Arias A, Carrasco I, Barreiro P, Peña JM, de Mendoza C. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxi-col. 2017 Sep;13(9):1015-1022. 37. Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterolo-gy. 2017 Jul;153(1):113-122. 38. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral–experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017 Jun;65(6):1803-1809. 39. Agencia Europea del Medicamento. Xermelo (TELOTRISTAT DE ETI-LO). Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/003937/smops/Positive/human_smop_001188. jsp&mid=WC0b01ac058001d127 40. Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econ. 2017 Oct 9:1-7. 41. Agencia Europea del Medicamento. Fotivda (TIVOZANIB HIDROCLO-RURO MONOHIDRATO). Disponible en: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/004131/smops/Positive/ human_smop_001165.jsp&mid=WC0b01ac058001d127 42. Rini BI, Atkins MB, Escudier BJ, Hutson TE, Koralewski P, McDermott DF,et al. Tivo-3: A phase 3, randomized, controlled, multi-center, open-la-bel study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal. 2017 ASCO Annual Meeting. J Clin Oncol 35, 2017 (suppl; abstr TPS4600). Disponible en: https://meetinglibrary.asco.org/ record/152434/abstract 43. Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, et al. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 Feb;131(3):603-610. 44. Rupp NJ, Montironi R, Mischo A, Moch H. Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come! - European Urology Supplements, 2017. In Press, Corrected Proof, Available online 12 September 2017.
REVISTA SANIDAD FAS OCT DIC 2017
To see the actual publication please follow the link above